CD93 gene polymorphism is associated with disseminated colorectal cancer

Olsen, Renate Slind; Lindh, Mikael; Vorkapić, Emina; Andersson, Roland; Zar, Niklas; Löfgren, Sture; Dimberg, Jan; Matussek, Andreas; Wågsäter, Dick

doi:10.1007/s00384-015-2247-1

Cited by 28 publications

(35 citation statements)

References 36 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Olsen RS et al had revealed that high expression of CD93 in colorectal cancer (CRC) was associated with two single nucleotide polymorphisms (SNPs, rs2749812 and rs2749817) and it could be a possible biomarker in CRC [33]. Chevrier S et al had reported that CD93 was an important molecular for the maintenance of plasma cells in bone marrow niches [34].…”

Section: Discussionmentioning

confidence: 98%

Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma

Bao

Tang

Zhang

et al. 2016

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma

Bao

Tang

Zhang

et al. 2016

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…cancer-specific death (Olsen et al, 2015), which is in agreement with other cancer studies (Langenkamp et al, 2015, Bao et al, 2016.…”

Section: N: N-terminus; S: Signal Peptide; Ctld: C-type Lectin-likesupporting

confidence: 82%

“…It has also been associated with different types of cancer such as breast cancer (Lee et al, 2009), glioblastoma (Langenkamp et al, 2015), CRC (Olsen et al, 2015) and nasopharyngeal carcinoma (Bao et al, 2016). In relation to cancer, CD93 has been associated with the risk of developing cancer (Lee et al, 2009).…”

Section: N: N-terminus; S: Signal Peptide; Ctld: C-type Lectin-likementioning

confidence: 99%

“…Several studies on cancer have implied that CD93 induces angiogenesis due to its increased expression in vascular endothelial cells and adhesion of endothelial cells (Orlandini et al, 2014, Olsen et al, 2015, Bao et al, 2016. Also, CD93 seem to be important for proper endothelial cell migration and vascular function (Langenkamp et al, 2015).…”

Section: N: N-terminus; S: Signal Peptide; Ctld: C-type Lectin-likementioning

confidence: 99%

See 1 more Smart Citation

Circulating and genetic factors in colorectal cancer: Potential factors for establishing prognosis?

Olsen¹

View full text Add to dashboard Cite

Colorectal cancer (CRC) is defined as a cancer appearing in the colon or in the rectum. In Sweden, ~ 6300 individuals were diagnosed with the disease in 2014 and ~ 2550 individuals diagnosed with CRC die each year due to their cancer. Surgery is the main treatment option of CRC and a survival rate of ~ 10 % is estimated if distant metastases have developed. It is therefore of importance to find factors that may be useful together with tumour, node, metastasis (TNM) stage to establish early CRC diagnosis, prognosis and follow-up of CRC patients. The aim of this thesis was to study the possible association of CD93, PLA2G4C, PDGF-D and inflammatory cytokines with CRC disease progression.In a prospective study approach CD93 and PLA2G4C single nucleotide polymorphisms (SNPs) were of potential importance in CRC prognosis.The T/T genotype of CD93 was associated with an increased CD93 expression in CRC tissue.Further, CRC patients carrying this genotype were associated with disseminated CRC at diagnosis and a lower recurrence-free survival after surgery. The A allele of a SNP of PLA2G4C was a stronger predictor for CRC-specific mortality than the conventional risk factors used in the clinic for selection of TNM stage II patients for adjuvant treatment. This indicates that the T/T genotype of CD93 and the A allele of PLA2G4C may be potential genetic factors related to disease severity and spread. Furthermore, they distinguish CRC patients that may benefit from a more comprehensive follow-up and adjuvant treatment.To study the putative involvement of PDGF-D in CRC the effects of PDGF-D signalling was studied in vitro. PDGF-D signalling altered the expression of genes of importance in CRC carcinogenesis and proliferation which was blocked by imatinib, a tyrosine kinase inhibitor.This indicates that PDGF-D signalling may be an important pathway in CRC progression and a potential target in CRC treatment.vi The analysis of various inflammatory cytokines in plasma at diagnosis showed an association between high levels and increased total-or CRC-specific mortality two years after surgery.High levels of CCL1 and CCL24 was the only cytokines strongly correlated with a worse CRC prognosis after statistical adjustments and may be of interest for further evaluation.In conclusion, this thesis presents circulating and genetic factors such as CD93, PLA2G4C, PDGF-D, CCL1 and CCL24 that may be of importance in CRC progression and may be of clinical value together with TNM stage in establishing prognosis. III.Olsen RS, Dimberg J, Geffers R, Wågsäter D. Possible role and therapeutic target of

show abstract

“…It is also highly expressed on the tumour‐associated vasculature. In a recent example, elevated levels of CD93 expression were detected on human colorectal carcinoma sections . Interestingly, this study also examined soluble levels of CD93 within patient plasma and found a 30% reduction in colorectal carcinoma patients compared with healthy controls.…”

Section: Cd93mentioning

confidence: 76%

C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation

et al. 2019

View full text Add to dashboard Cite

The C‐type lectin domain (CTLD) group 14 family of transmembrane glycoproteins consist of thrombomodulin, CD93, CLEC14A and CD248 (endosialin or tumour endothelial marker‐1). These cell surface proteins exhibit similar ectodomain architecture and yet mediate a diverse range of cellular functions, including but not restricted to angiogenesis, inflammation and cell adhesion. Thrombomodulin, CD93 and CLEC14A can be expressed by endothelial cells, whereas CD248 is expressed by vasculature associated pericytes, activated fibroblasts and tumour cells among other cell types. In this article, we review the current literature of these family members including their expression profiles, interacting partners, as well as established and speculated functions. We focus primarily on their roles in the vasculature and inflammation as well as their contributions to tumour immunology. The CTLD group 14 family shares several characteristic features including their ability to be proteolytically cleaved and engagement of some shared extracellular matrix ligands. Each family member has strong links to tumour development and in particular CD93, CLEC14A and CD248 have been proposed as attractive candidate targets for cancer therapy.

show abstract

CD93 gene polymorphism is associated with disseminated colorectal cancer

Cited by 28 publications

References 36 publications

Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma

Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma

Circulating and genetic factors in colorectal cancer: Potential factors for establishing prognosis?

C‐type lectin domain group 14 proteins in vascular biology, cancer and inflammation

Contact Info

Product

Resources

About